Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recessive Dystrophic Epidermolysis Bullosa: later-stage trial registry
3 of 6 indexed Recessive Dystrophic Epidermolysis Bullosa trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 3 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Recessive Dystrophic Epidermolysis Bullosa: 6 US clinical trials tracked, 3 recruiting.
Recessive Dystrophic Epidermolysis Bullosa is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Abeona Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition recessive-dystrophic-epidermolysis-bullosa
OPEN 3 | RECR 50% | LATE 4 | EARLY 1 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Achalasia (50% recruiting · 8 trials)
Recessive Dystrophic Epidermolysis Bullosa lists 3 open slots (50% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recessive Dystrophic Epidermolysis Bullosa on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recessive Dystrophic Epidermolysis Bullosa is recruiting above its size-band peers.
3 of 6 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recessive Dystrophic Epidermolysis Bullosa research.
Abeona Therapeutics accounts for 2 of 6 trials (33.3%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Recessive Dystrophic Epidermolysis Bullosa trials plan to enrol fewer than 100 people.
Median target enrolment is 12 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.
-
Recessive Dystrophic Epidermolysis Bullosa research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Long-Term Follow-up Protocol
Krystal Biotech
NCT04917887
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
Krystal Biotech
NCT07016750
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
M. Peter Marinkovich
NCT06834035
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Abeona Therapeutics
NCT05725018
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
Castle Creek Biosciences
NCT04213261
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Abeona Therapeutics
NCT04227106
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Recessive Dystrophic Epidermolysis Bullosa records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recessive Dystrophic Epidermolysis Bullosa trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recessive Dystrophic Epidermolysis Bullosa page
6 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Recessive Dystrophic Epidermolysis Bullosa trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abeona Therapeutics sponsors the most Recessive Dystrophic Epidermolysis Bullosa trials on record, review their full trial history before evaluating a specific study. See Abeona Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recessive Dystrophic Epidermolysis Bullosa condition card totals 6 registered trials; most-linked intervention EB-101; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.